1. Harris JC. Intellectual disability: understanding its development, causes, classification, evaluation and treatment. New York: Oxford Press; 2008.
2. Barnhill LJ, Barnhill SK. The role of cultural factors and deinstitutionalization of persons with mental retardation: a view from the rural south. NADD Bull. 2002;5(5):87–93.
3. Deb S, Fraser W. The use of medication in people with learning disability: towards more rational prescribing. Hum Psychopharmacol. 1994;9:259–72.
4. Kane J. Issues in clinical trial designs. In: David KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Baltimore: Lippincott Williams Wilkins; 2002. p. 537–48.
5. Alves FS, Fijee M, van Amelsvoort T, Veltman D, de Haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medications. Psychopharmacol Bull. 2008;41(1):121–32.